Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

Q4 2025 Earnings Call March 30, 2026 4:30 PM EDTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid Margrave ...

Preliminary Results for the Year Ended 31 December 2025

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company’s lead development ...

Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2025

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...

Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify

Sharma announced a Type C meeting with the FDA scheduled for mid-May 2026, seeking feedback on protocol amendments for LP-300, focusing on patient enrollment with the EGFR exon 21 L858R mutation, ...